Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein

Cell Commun Signal. 2019 Nov 19;17(1):150. doi: 10.1186/s12964-019-0469-5.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Apoptosis Regulatory Proteins / antagonists & inhibitors
  • Apoptosis Regulatory Proteins / metabolism*
  • Bone Morphogenetic Protein Receptors, Type II / antagonists & inhibitors
  • Bone Morphogenetic Protein Receptors, Type II / metabolism*
  • Cell Death / drug effects
  • Cell Survival / drug effects
  • Cytosol / drug effects
  • Cytosol / metabolism*
  • Down-Regulation* / drug effects
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Mitochondrial Proteins / antagonists & inhibitors
  • Mitochondrial Proteins / metabolism*
  • Signal Transduction / drug effects
  • Tumor Cells, Cultured
  • X-Linked Inhibitor of Apoptosis Protein / antagonists & inhibitors
  • X-Linked Inhibitor of Apoptosis Protein / metabolism*

Substances

  • Apoptosis Regulatory Proteins
  • DIABLO protein, human
  • Enzyme Inhibitors
  • Mitochondrial Proteins
  • X-Linked Inhibitor of Apoptosis Protein
  • XIAP protein, human
  • BMPR2 protein, human
  • Bone Morphogenetic Protein Receptors, Type II